Eli Lilly stock receives analyst upgrades and high price targets

Eli Lilly and Company has received significant analyst upgrades, with Citigroup establishing a $1,600 price target. This represents a potential 45% upside from the stock’s recent trading value of $1,138. Citigroup analyst Geoff Meacham reaffirmed a Buy recommendation, citing the company’s dominant 60% share of the global weight-loss medication market.

Berenberg also expressed bullish sentiment, elevating its rating from Hold to Buy and raising its price target to $1,400. The pharmaceutical company’s financial strength is driven by its flagship products, Zepbound and Mounjaro, which target obesity and diabetes and have generated $14.9 billion in combined quarterly revenue.